Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
Why this paper is included
Supporting source evidence:
Accordingly, we analyzed (Supplemental Figure 5) the effect of ERFE overexpression on serum phosphate and iFGF23 (biologically active form) concentrations, as well as markers of mineral metabolism, including Slc34a1 and Slc34a3 (encoding sodium-dependent phosphate transporters 2A and 2C, also known as NaPi-2a and -2c), Cyp27b1 and Cyp24a1 (encoding the enzymes that respectively generate and break down the active form of vitamin D, 1,25-dihydroxyvitamin D3), and Kl (encoding Klotho, the renal coreceptor for iFGF23).
Source: Results. View original paper
Relevance classification does not establish study quality, causation or editorial approval.
Study design Study design awaiting verification.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.
Meta-analysis unclear · Blinding unclear / not reported · Animal research reported
How this paper was classified
Automatic source-based classification; awaiting editorial verification. This is not a quality score.
Mice were maintained in a ventilated rodent-housing system in temperature-controlled environments (22°C: 25°C) with a 12-hour light/dark cycle, and allowed ad libitum access to food and water.
Source: Methods.
What the study types mean
- Systematic review
- Uses explicit methods to identify, assess and summarise research on a defined question.
- Scoping review
- Maps the extent and characteristics of research on a topic.
- Narrative review
- Discusses existing research; systematic-review methods have not been established by this classification.
- Review / evidence synthesis
- Reviews existing research; the exact review methods need further assessment.
- Randomised controlled trial
- Assigns participants or groups to comparison interventions by chance.
- Non-randomised intervention study
- Examines an intervention without random allocation.
- Cohort study
- Examines exposures and outcomes over time within a defined group.
- Case-control study
- Compares people with an outcome against people without it, examining exposures.
- Cross-sectional study
- Examines a population at a particular point in time.
- Observational study
- Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
- Case report
- Describes an individual case.
- Case series
- Describes a group of individual cases.
- Secondary analysis
- Analyses existing study data; this paper is not automatically another independent trial.
- Laboratory study
- Investigates biological processes in a laboratory setting.
- Qualitative study
- Examines experiences or meanings using qualitative methods.
- Genetic instrumental-variable study
- Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
- Study protocol
- Describes planned methods and is not evidence that the planned study has reported results.
- Multiple reported designs
- More than one design is explicitly reported; examine the supporting methods.
- Study design awaiting verification
- The available source does not establish a sufficiently clear study design.
Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.
Abstracts
Transgenic augmentation of erythroferrone in mice ameliorates anemia in adenine-induced chronic kidney disease
Study design awaiting verification · JCI Insight · 2025
Original publication title
Transgenic augmentation of erythroferrone in mice ameliorates anemia in adenine-induced chronic kidney disease
© 2025 Czaya et al.
Original publication · Publisher record · CC BY 4.0
Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.
At a glance
What does the authors’ abstract report?
Anemia is a common and disabling complication of chronic kidney disease (CKD). Current therapies can be burdensome, and full correction of anemia is limited by their cardiovascular side effects. New approaches that may offer additional therapeutic options are needed. We explored the antianemic effects of erythroferrone, an erythroid hormone that induces iron mobilization by suppressing the master iron-regulatory hormone hepcidin. In a preclinical murine model of adenine-induced CKD, transgenic augmentation of erythroferrone mobilized iron, increased hemoglobin concentrations by approximately 2 g/dL, and modestly improved renal function without affecting systemic or renal inflammation, fibrosis, or markers of mineral metabolism.
This study supports the concept that therapeutic augmentation of erythroferrone is a promising approach for alleviating CKD-associated anemia.
Authors’ abstract
Anemia is a common and disabling complication of chronic kidney disease (CKD). Current therapies can be burdensome, and full correction of anemia is limited by their cardiovascular side effects. New approaches that may offer additional therapeutic options are needed. We explored the antianemic effects of erythroferrone, an erythroid hormone that induces iron mobilization by suppressing the master iron-regulatory hormone hepcidin. In a preclinical murine model of adenine-induced CKD, transgenic augmentation of erythroferrone mobilized iron, increased hemoglobin concentrations by approximately 2 g/dL, and modestly improved renal function without affecting systemic or renal inflammation, fibrosis, or markers of mineral metabolism.
This study supports the concept that therapeutic augmentation of erythroferrone is a promising approach for alleviating CKD-associated anemia.
Publication and source details
Original title: Transgenic augmentation of erythroferrone in mice ameliorates anemia in adenine-induced chronic kidney disease
Brian Czaya; Joseph D. Olivera; Moya Zhang; Amber Lundin; Christian D. Castro; Grace Jung; Mark R. Hanudel; Elizabeta Nemeth; Tomas Ganz
JCI Insight · 2025
Address correspondence to: Tomas Ganz, Center for Iron Disorders, Department of Medicine, David Geffen School of Medicine at UCLA, 10833 Le Conte Ave., Los Angeles, California 90095-1690, USA. Email: tganz@mednet.ucla.edu.© 2025 Czaya et al.2025Czaya et al.https://creativecommons.org/licenses/by/4.0/This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.NIDDKR01 DK126680 NHLBI Division of Intramural Researchhttps://doi.org/10.13039/100017540 T32 HL072752 Howard Hughes Medical Institutehttps://doi.org/10.13039/100000011 Gilliam Fellowship Ford Foundation Fellowship Programshttps://doi.org/10.13039/100030613 FellowshipThis study was supported by the National Institutes of Health through R01 DK126680 (TG, EN) with supplement (JDO), training grant T32 HL072752 (BC), and Ford Foundation Fellowship and Gilliam/Howard Hughes Medical Institute Fellowship (CDC).Repository JATS snapshot; version as supplied
Source retrieved: 2026-11-11T03:34:40.062504+00:00
DOI: 10.1172/jci.insight.190018 · PMC12487854